**Alpha Cognition Inc. Reports Fiscal Year 2025 Results, Focuses on ZUNVEYL Commercialization**

Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative diseases, reported its financial results for the fiscal year ended December 31, 2025. The company generated total revenue of $10.2 million, which included $6.8 million in net product sales from ZUNVEYL, its FDA-approved treatment for mild-to-moderate Alzheimer's disease, and $3.4 million in licensing revenue. This marks a significant increase from the previous fiscal year, where the company reported no revenue as it was still in the pre-commercialization phase. The company's net loss for the year was $20.7 million, or $1.17 per share, compared to a net loss of $14.8 million, or $2.04 per share, in the prior year.

The company's operating expenses totaled $32.9 million, a substantial increase from $12.0 million in the previous year. This increase was primarily driven by higher selling, general, and administrative expenses, which rose to $29.1 million due to the commercial launch of ZUNVEYL and related marketing and sales activities. Research and development expenses decreased to $1.9 million from $3.9 million in the prior year, reflecting a shift in focus towards commercialization. Cost of product sales was $0.5 million and cost of licensing revenue was $1.4 million, both of which were new expenses due to the commercialization of ZUNVEYL and the licensing agreement with CMS International Development and Management Limited (CMSI).

Key operational developments included the commercial launch of ZUNVEYL on March 19, 2025, targeting long-term care facilities specializing in Alzheimer's disease. The company also entered into an exclusive licensing agreement with CMSI for the development, manufacturing, and commercialization of ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand. The company has established commercial supply of ZUNVEYL and has executed agreements with two of the four major national Pharmacy Benefit Managers (PBMs). The Wholesale Acquisition Cost (WAC) for ZUNVEYL has been set at $820 per month.

Looking ahead, Alpha Cognition plans to continue executing its commercialization strategy for ZUNVEYL, focusing on the long-term care market and securing formulary coverage with payors. The company also intends to pursue non-dilutive funding sources for its pre-clinical assets, including ALPHA-1062 for Cognitive Impairment with mTBI. Alpha Cognition believes it has sufficient capital to achieve operating profitability by 2027, provided it executes its commercial plan in the long-term care market and does not advance compounds in the pipeline. The company had 71 full-time employees as of the end of the fiscal year.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, primarily Alzheimer's. Its key product, ZUNVEYL, is a next-generation acetylcholinesterase inhibitor approved for mild to moderate dementia. The company also advances pre-clinical programs targeting cognitive impairment, traumatic brain injury, and other neurodegenerative conditions, leveraging innovative formulations and strong intellectual property to address unmet medical needs in aging populations.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.